Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Posaconazole in Chinese Patients at High Risk for Invasive Fungal Infections
NCT02387983Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of posaconazole in invasive fungal infection (IFI), sponsored by Merck & Co. Primary endpoints: Steady-state Average Concentration of Posaconazole at Day 8, Steady-state Area Under the Concentration-time Curve of Posaconazole at Day 8 and 7 more. Started May 2015; status: completed.
02
Drugs
posaconazole
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT02387983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387983.